Residency · Residency · Orthopedic Surgery

Approach to the Musculoskeletal Tumor: Systematic Evaluation

Introduction

Musculoskeletal tumors range from common benign lesions requiring no treatment to aggressive malignancies demanding urgent multidisciplinary intervention. The general orthopedic surgeon must be able to recognize concerning features, initiate an appropriate workup, and avoid actions that could compromise definitive treatment. A systematic approach to evaluation prevents errors that may lead to unnecessary amputation or worse oncologic outcomes.

Principles of Evaluation

The cardinal rule is to do no harm: an improperly performed biopsy or premature surgical intervention can contaminate tissue planes and compromise limb salvage. The systematic sequence is history, physical examination, imaging, staging, then biopsy. Referral to a musculoskeletal oncology center should occur before biopsy whenever a malignant bone or soft tissue tumor is suspected. The Mankin study demonstrated that errors in biopsy and initial management by non-oncology surgeons led to unnecessary amputations and poorer outcomes in up to 20% of cases.

Clinical Evaluation

History

Age is the single most important demographic factor, as specific tumors cluster by age group. In patients 0-10 years, consider Ewing sarcoma, Langerhans cell histiocytosis, and osteofibrous dysplasia. In the 10-30 age range, osteosarcoma, Ewing sarcoma, and giant cell tumor predominate. Between 30-50 years, GCT (skeletally mature) and soft tissue sarcomas are common. Over age 50, metastatic disease, myeloma, chondrosarcoma, and Paget sarcoma should be considered.

The pain pattern provides important clues: night pain and rest pain suggest aggressive or malignant lesions, while mechanical pain is more typical of benign processes. Constitutional symptoms (weight loss, fever, fatigue) suggest systemic disease such as Ewing sarcoma, lymphoma, or metastasis. Rapid growth is concerning for malignancy. A history of prior malignancy should always raise suspicion for metastatic disease.

Physical Examination

For soft tissue masses, size greater than 5 cm increases the likelihood of malignancy. Deep-seated masses (below the fascia) are more commonly malignant than superficial lesions. Firm, fixed masses are more concerning than mobile, soft lesions. Associated findings such as lymphadenopathy, hepatosplenomegaly, and skin changes should be noted. Neurovascular status of adjacent structures must be documented.

Imaging

Plain Radiographs

Plain radiographs are the most important initial imaging study for bone lesions. Systematic analysis evaluates: location within the bone (epiphyseal suggests GCT, metaphyseal suggests osteosarcoma or chondrosarcoma, diaphyseal suggests Ewing sarcoma or lymphoma); location within the skeleton (axial vs. appendicular); lesion borders (well-defined sclerotic margin indicates benign, slow-growing process versus permeative/moth-eaten pattern indicating aggressive/malignant behavior); matrix (osteoid matrix with cloud-like, amorphous density suggests osteosarcoma, while chondroid matrix with rings and arcs or popcorn calcification suggests a chondroid lesion); periosteal reaction (solid/thick indicates benign and slow while lamellated onion-skin suggests Ewing, and sunburst or Codman triangle indicates aggressive behavior suggesting osteosarcoma); soft tissue mass extending beyond the cortex (suggesting aggressive behavior); and number of lesions (polyostotic suggests metastatic disease, multiple myeloma, or fibrous dysplasia).

MRI

MRI is essential for local staging of both bone and soft tissue tumors. It evaluates the extent of marrow involvement, soft tissue extension, and relationship to neurovascular structures. T1-weighted images best demonstrate marrow replacement (tumor appears dark, replacing bright fatty marrow). T2-weighted/STIR images show tumor edema and extent as bright signal. Gadolinium enhancement helps differentiate solid tumor from cystic/necrotic areas and aids biopsy planning. MRI of the entire involved bone is mandatory to detect skip metastases.

CT Scan

CT is best for evaluating cortical integrity, matrix mineralization, and lung metastases (CT chest for staging). Thin-cut CT with 3D reconstruction aids surgical planning.

Bone Scan (Technetium-99m)

Bone scan evaluates the entire skeleton for multifocal disease with high sensitivity but low specificity. It is useful for screening for metastatic disease and polyostotic involvement.

PET-CT

PET-CT is increasingly used for staging and treatment response assessment, particularly for Ewing sarcoma and soft tissue sarcomas. It evaluates metabolic activity of lesions.

Staging

Enneking Staging System (Musculoskeletal Tumor Society)

Benign tumors are staged as Stage 1 (Latent) (well-encapsulated, incidental findings requiring no treatment, such as non-ossifying fibroma), Stage 2 (Active) (symptomatic, may slowly enlarge but remains contained, such as active unicameral bone cyst), or Stage 3 (Aggressive) (locally destructive, may breach compartmental boundaries, such as giant cell tumor or aneurysmal bone cyst).

Malignant tumors are staged as Stage IA (low grade, intracompartmental), Stage IB (low grade, extracompartmental), Stage IIA (high grade, intracompartmental), Stage IIB (high grade, extracompartmental, the most common presentation of primary bone sarcomas), or Stage III (any grade with regional or distant metastases).

Biopsy

Principles

The biopsy is the last step in the workup, not the first. It should be performed by or in consultation with the surgeon who will perform the definitive procedure. The biopsy tract must be excisable with the definitive resection specimen, planned in alignment with the treating oncologic surgeon's approach.

Open Biopsy

Incisional biopsy is the gold standard, providing adequate tissue for histology, immunohistochemistry, and molecular studies. A longitudinal incision in line with the planned definitive surgical approach is used. Contamination is minimized by staying within one compartment and achieving meticulous hemostasis. Drains should be avoided when possible; if used, the drain exit should be in line with the incision.

Core Needle Biopsy (CNB)

Core needle biopsy is increasingly used as the primary biopsy technique at specialized centers, performed under image guidance (CT, ultrasound, fluoroscopy). Diagnostic accuracy exceeds 90-95% at high-volume centers. It produces less contamination of tissue planes than open biopsy but may be insufficient for certain diagnoses requiring architectural assessment.

Fine Needle Aspiration (FNA)

FNA has a limited role in primary bone and soft tissue tumor diagnosis but may be useful for confirming metastatic disease or recurrence of a known tumor.

Common Pitfalls

Common pitfalls include performing an excisional biopsy of a lesion presumed benign that turns out to be malignant (the unplanned excision or "whoops" procedure), using a transverse incision that contaminates multiple compartments, failing to obtain adequate imaging before biopsy, performing biopsy through a path that cannot be included in the definitive resection, and fixation of a pathologic fracture without first establishing a tissue diagnosis.

Key Clinical Pearls

The most important initial imaging study for a bone lesion is the plain radiograph; a systematic analysis of location, borders, matrix, and periosteal reaction narrows the differential diagnosis significantly. Refer to a musculoskeletal oncology center before biopsy whenever malignancy is suspected; an improperly placed biopsy can compromise limb salvage. Age is the most powerful demographic variable in narrowing the differential diagnosis of a bone tumor; always consider metastatic disease and myeloma in patients over 40. Any bone lesion causing unexplained pain, particularly night pain, in a patient under 30 should be evaluated with a high index of suspicion for primary bone malignancy.

References

1. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. J Bone Joint Surg Am. 1996;78(5):656-663.
2. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;(153):106-120.
3. Errani C, Traina F, Perna F, et al. Current concepts in the biopsy of musculoskeletal tumors. J Bone Joint Surg Am. 2013;95(14):e101.
4. Miller TT. Bone tumors and tumorlike conditions: analysis with conventional radiography. Radiology. 2008;246(3):662-674.

Read this lecture as Markdown